Neutrosophic method for the recommendation in the identification of Duchenne Muscular Dystrophy

Abstract

Duchenne Muscular Dystrophy (DMD) is an X-linked genetic disease, clinically characterized by causing progressive muscle weakness. This pathology has an incidence of 1 per 3,500-6,000 male births, caused by the mutation of the DMD gene, which encodes dystrophin. This protein is subsarcolemic, characterized by being essential for structural muscle stability. Currently there is no effective therapeutic treatment, the only drug that has been shown to modify the natural history of the disease has been corticosteroids. The objective of this research is to develop a neutrosophic method for the recommendation in the identification of Duchenne Muscular Dystrophy. A cross-sectional analytical study of descriptive origin with retrospective characteristics and prospective purposes will be carried out. Also, random sampling will be used in the clinical history and DMD disease at the Ambato Teaching Hospital during the period 2022. This information is recorded in a form designed to feed the input information of the neutrosophic method of recommendation. Although there is currently no curative treatment available, there are strategies that allow the natural evolution of the disease and the appearance of complications to be delayed.